Pathologically confirmed malignant syphilis in an HIV-infected patient.

Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Japan.
Internal Medicine (Impact Factor: 0.97). 01/2011; 50(20):2423-6. DOI: 10.2169/internalmedicine.50.5605
Source: PubMed

ABSTRACT We report a case of pathologically confirmed malignant syphilis in an HIV-infected patient. Physical examinations revealed ulceronecrotic skin lesions. Skin biopsies demonstrated syphilis spirochetes on immunohistochemical stain, and syphilis serological titers were positive. Treatment with intravenous penicillin G was begun, and complete resolution of the skin lesions was observed. A rapid plasma reagin titer test performed 3 months after treatment revealed a 4-fold reduction in the titer, indicating successful treatment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant syphilis in a patient infected by human immunodeficiency virus. Case report and literature review Malignant syphilis is a rare form of secondary syphilis strongly associated with human immunodeficiency virus infection (HIV). This clinical form of the disease is characterized by atypical cutaneous ulcerative and disseminated lesions and systemic compromise that can delay the final diagnosis. There are only few reports in the medical literature about malignant lues in HIV-infected patients. Malignan syphilis should be considered in the differential diagnosis in HIV-infected patients with fever and ulcerative skin lesions. Here we describe a man who developed clinical cutaneous and systemic manifestations pathologically confirmed as malignant syphilis and we performed a review of the literature. Introducción L a sífilis maligna es una forma clínica grave de esta enfermedad que en la actualidad se observa en asociación con la infección por el virus de la inmunodeficiencia humana (VIH). Se caracteriza por manifestaciones clínicas inespecíficas y lesiones cutáneas extensas, polimorfas, destructivas y ulcerativas, algunas con características rupioides, que pueden comprometer la vida del paciente. Las lesiones papulosas, nodula-res y ulcerativas pueden estar cubiertas por costras y evolucionan en forma lenta hacia la cicatrización 1,2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La sífilis maligna es una forma rara de presentación de lúes secundaria asociada a la infección por el virus de la inmunodeficiencia humana (VIH). Se caracteriza por lesiones cutáneas atípicas, ulceradas, costrosas y diseminadas, asociadas con síntomas generales inespecíficos que pueden retrasar el diagnóstico correcto. Existen sólo escasas publicaciones en la literatura médica acerca de sífilis maligna en pacientes con infección por VIH. La lúes maligna debe incluirse en el diagnóstico diferencial de los pacientes con VIH que consultan por fiebre y lesiones úlcero-costrosas diseminadas. Se describe el caso de un paciente con infección por VIH que desarrolló una sífilis maligna con confirmación diagnóstica a partir de los hallazgos histopatológicos y se realiza una revisión de la literatura científica sobre el tema.
    Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia 12/2012; 29(6):678-681. · 0.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous signs and skin conditions associated with sexually transmitted infections (STIs) are discussed. Syphilis, condyloma acuminata, and scabies are well-known STIs with cutaneous manifestations. Chlamydia and gonorrhea can also cause specific muco-cutaneous signs and symptoms. HIV often manifests itself through skin conditions. Dermatologists are pivotal in the timely diagnosis of HIV infection and play an important role in the disease prognosis and ongoing transmission. Anal intra-epithelial neoplasia (AIN), an HPV related precursor of anal carcinoma affecting HIV positive men, is a relatively new condition that many dermatologists will face in the future. STIs should be involved in the differential diagnosis when dermatologists are confronted with anogenital dermatoses, especially in patients with an increased risk for STIs.
    Clinics in dermatology 03/2014; 32(2):196-208. · 3.11 Impact Factor